TT
Transcend Therapeutics
OrganizationHeard in 12 episodes across 8 shows since Mar 2026
Transcend Therapeutics is a clinical-stage biotechnology company developing rapid-acting treatments for neuropsychiatric disorders. Its lead investigational candidate, TSND-201 (methylone), is being developed for post-traumatic stress disorder (PTSD) and has received FDA Breakthrough Therapy designation.
Episodes
12
across 8 shows
First heard
Mar 2026
Episodes per month
Public PodLume episodes featuring it, over the last year.
1
2
7
2
Show the data
| Month | Episodes |
|---|---|
| Nov 2025 | 0 |
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 1 |
| Apr 2026 | 0 |
| May 2026 | 0 |
| Jun 2026 | 0 |
| Jul 2026 | 0 |
| Aug 2026 | 2 |
| Sep 2026 | 7 |
| Oct 2026 | 2 |
Episodes
12 episodes featuring Transcend Therapeutics, newest first
- Oct 8, 2026
AI agents need governance before companies scale themInside AsembleAI: DeepTech, AI & ScienceOct 8, 2026 - Oct 4, 2026
Portfolio losses test conviction in Axon, QXO and Hub24Equity Mates Investing PodcastOct 4, 2026 - Sep 30, 2026
Strata bets on logistics as transplant technology fragmentsMicroCapClubSep 30, 2026 - Sep 24, 2026
Oracle’s AI commitments expose cracks in the infrastructure boomMotley Fool Hidden Gems InvestingSep 24, 2026 - Sep 24, 2026
Kevin Ryan bets on durable trends over startup hypeThe Tim Ferriss ShowSep 24, 2026 - Sep 18, 2026
Australia’s psychedelic breakthrough offers advocates a regulatory playbookThe Tim Ferriss ShowSep 18, 2026